A New Turning Point in Biotechnology: The Rapid Growth of AI Integration and Personalized Medicine by 2025
Editor
Industry Innovation Driven by AI and Biotechnology Integration
In 2025, the biotechnology industry is reaching a historic turning point through its integration with artificial intelligence. The global biotech market size is projected to grow from $980 billion in 2024 to $1.2 trillion in 2025, a 22.4% increase, according to McKinsey Global Institute. The key drivers of this rapid growth are the commercialization of AI-based drug development platforms and the full-scale market entry of personalized therapies. Notably, technologies such as protein structure prediction and drug-target interaction analysis using machine learning algorithms are reducing new drug development timelines from the traditional 10-15 years to 5-7 years, prompting a paradigm shift across the pharmaceutical industry.
South Korea’s biotech ecosystem plays a significant role in these global trends. Samsung Biologics, headquartered in Incheon, recorded a 34% year-on-year increase in revenue, reaching 2.8 trillion won by the third quarter of 2025, capturing a 17.3% share of the global biopharmaceutical contract manufacturing (CMO) market. The company has introduced an AI-based production optimization system, improving production efficiency by 28%, which serves as a key competitive advantage in meeting global pharmaceutical companies’ demands for cost reduction. Meanwhile, Celltrion, located in Songdo, has established an AI-driven quality management system in the biosimilar sector, increasing FDA approval success rates from 72% to 89%.
Major U.S. pharmaceutical companies are also actively adopting AI technologies. Johnson & Johnson, headquartered in New Jersey, announced a $4.7 billion investment in AI-based drug development by 2025, accounting for 31% of its total R&D budget. The company’s AI platform is currently analyzing 134 candidate substances, with 23 entering Phase 1 clinical trials. Similarly, Pfizer, based in New York, identified eight new therapeutic candidates in the first half of 2025 through its AI-based drug discovery platform, a 60% increase from previous figures. AI plays a crucial role in Alzheimer’s treatment development, improving clinical trial success rates from 12% to 23%.
The rapid growth of the Precision Medicine market is also noteworthy. The global personalized medicine market is valued at $284 billion by 2025, with an annual growth rate of 13.8%. Roche, headquartered in Basel, Switzerland, holds a leading position in this field. Roche’s personalized cancer therapy portfolio recorded $18.9 billion in sales by the third quarter of 2025, accounting for 42% of total revenue. The company’s HER2-positive breast cancer treatment, Kadcyla, improved treatment response rates from 76% to 84% through an AI-based patient selection system.
Accelerating Commercialization of Gene Editing and Cell Therapy
The commercialization of CRISPR gene editing technology is emerging as another growth driver for the biotech industry in 2025. The global CRISPR market size increased by 31% to $8.9 billion in 2025, with Grand View Research forecasting an annual growth rate of 28.5% through 2030. This growth is driven by the accelerated FDA approval of rare genetic disorder treatments. In 2025 alone, seven CRISPR-based therapies received FDA approval, more than doubling from three in 2024.
In the Cell Therapy sector, CAR-T therapies are expanding their application scope, driving market growth. The global CAR-T cell therapy market is valued at $12.7 billion by 2025, rapidly growing as indications expand from hematologic cancers to solid tumors. Moderna, headquartered in Massachusetts, is leading innovation in the personalized cancer vaccine field using mRNA technology. The company’s personalized cancer vaccine, mRNA-4157, showed a 44% reduction in recurrence rates in Phase 3 trials for melanoma patients, with commercialization targeted for 2026.
Advancements in gene sequencing technology are also accelerating the spread of personalized treatments. Illumina, based in San Diego, California, launched the NovaSeq X Plus next-generation sequencing (NGS) platform in 2025, reducing the cost of whole-genome sequencing to $200. This is 0.000007% of the $2.7 billion cost at the completion of the Human Genome Project in 2003, making the popularization of personalized treatments a reality. Illumina’s third-quarter 2025 revenue increased by 18% year-on-year to $1.24 billion, with oncology sector revenue surging by 41%.
Korean biotech companies are actively participating in these global trends. Celltrion initiated Phase 2 clinical trials for its CAR-T cell therapy CT041 in the second half of 2025, marking the first self-developed CAR-T therapy by a Korean company. The company invested 280 billion won in developing this therapy, targeting commercialization by 2028. Additionally, Samsung Biologics is preparing to enter the global cell therapy CMO market by establishing a dedicated facility for cell therapy production at the Songdo Bio Campus.
The convergence of digital healthcare and biotechnology is also creating new market opportunities. The predictive healthcare market, combining real-time biometric data collection through wearable devices with AI analysis, is rapidly growing, shifting the paradigm to preventive, personalized treatments. The global digital healthcare market is valued at $659 billion by 2025, emerging as a new revenue source for biotech companies. The effectiveness of digital-bio convergence solutions in managing diabetes and cardiovascular diseases has been demonstrated, leading to expanded insurance coverage.
Changes in the regulatory environment are also supporting the growth of the biotech industry. The FDA announced new guidelines for AI-based drug development in 2025, streamlining the approval process. As a result, the clinical trial approval period for AI-based therapies has been reduced from 18 months to 12 months, positively impacting funding and development timelines for biotech startups. The European Medicines Agency (EMA) has implemented similar regulatory easing measures, accelerating the growth of the global biotech market.
The biotechnology industry has entered a new growth trajectory in 2025 through the integration of AI, personalized medicine, and the commercialization of gene editing technologies. With the global market size surpassing $1.2 trillion, technological innovation and increased investment by major companies, including those in Korea, continue. The improved success rates and shortened development timelines of AI-based drug development enhance overall industry efficiency, providing patients with more effective and personalized treatment options. As regulatory environments continue to improve and the integration with digital healthcare expands, the biotech industry is expected to lead the digital transformation of the entire healthcare ecosystem.
The information presented in this post is for general informational purposes only and should not be construed as investment advice. Please consult a financial advisor before making investment decisions.
